EndoSphere, Inc. developed a weight loss device, SatiSphere‚ĄĘ Systems, with the intent to treat obesity and associated type 2 diabetes. With over 30 issued and pending patents, SatiSphere¬†utilizes the body’s natural physiology to accelerate weight-loss, with the goal of creating a sustainable lifestyle for patients post-treatment.

Additional Investors:
Broadline Capital, Glengary Ventures, Ohio TechAngels, Queen City Angels, Rev1 Ventures